Abstract
No public abstract is available from the verified source records.
Suzanne Y. Ngo, William C. Anderson
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Advances in asthma: new understandings of asthma's natural history, risk factors, underlying mechanisms, and clinical management
10.1016/j.jaci.2021.10.001 · 2021
Recent advances in severe asthma: from phenotypes to personalized medicine
10.1016/j.chest.2019.10.009 · 2020
Features of asthma which provide meaningful insights for understanding the disease heterogeneity
10.1111/cea.13014 · 2018
A modern approach to identifying and characterizing child asthma and wheeze phenotypes based on clinical data
10.1371/journal.pone.0227091 · 2019
Heterogeneity of mild to moderate persistent asthma in children: confirmation by latent class analysis and association with 1-Year outcomes
10.1016/j.jaip.2020.02.032 · 2020
Change in the manifestations of asthma and asthma-related traits in childhood: a latent transition analysis
10.1183/13993003.00284-2015 · 2016
Sputum inflammatory phenotypes are not stable in children with asthma
10.1136/thoraxjnl-2011-201064 · 2012
Exacerbation profile and risk factors in a Type-2-Low enriched severe asthma cohort: a clinical trial to assess asthma exacerbation phenotypes
10.1164/rccm.202201-0129oc · 2022
Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications
10.1111/cea.12880 · 2017
T-helper type 2-driven inflammation defines major subphenotypes of asthma
10.1164/rccm.200903-0392oc · 2009
Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma
10.1111/cea.13790 · 2021
Mechanisms and therapeutic strategies for non-T2 asthma
10.1111/all.13985 · 2020
Toward clinically applicable biomarkers for asthma: an EAACI position paper
10.1111/all.13806 · 2019
Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma
10.1111/all.12101 · 2013
2020 focused updates to the asthma management guidelines: a report from the national Asthma Education and Prevention Program Coordinating Committee expert Panel Working Group
10.1016/j.jaci.2020.10.003 · 2020
Exhaled nitric oxide is only an asthma-relevant biomarker among children with allergic sensitization
10.1111/pai.14044 · 2023
Recent insights in the role of biomarkers in severe asthma management
2022
Gina 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents
10.1183/13993003.01046-2019 · 2019
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study
10.1016/s2213-2600(20)30416-1 · 2021
Inhaled combined budesonide-formoterol as needed in mild asthma
10.1056/nejmoa1715274 · 2018
Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial
10.1016/s0140-6736(25)00861-x · 2025
Pivotal efficacy trials of inhaled corticosteroids in asthma
10.1016/j.anai.2016.07.035 · 2016
Biomarker-based asthma phenotypes of corticosteroid response
10.1016/j.jaci.2014.10.026 · 2015
Markers of differential response to inhaled corticosteroid treatment among children with mild persistent asthma
10.1016/j.jaip.2015.01.023 · 2015
Correlations between exhaled nitric oxide, rs28364072 polymorphism of FCER2 gene, asthma control, and inhaled corticosteroid responsiveness in children with asthma
10.1088/1752-7163/abc4ec · 2020
Integrative approach identifies corticosteroid response variant in diverse populations with asthma
10.1016/j.jaci.2018.09.034 · 2019
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
10.1016/j.jaci.2004.11.014 · 2005
Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma
10.1016/j.jaci.2008.11.016 · 2009
Individualized therapy for persistent asthma in young children
10.1016/j.jaci.2016.09.028 · 2016
Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma
10.1164/rccm.200407-884oc · 2005
Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma
10.1378/chest.130.6.1733 · 2006
Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment
10.1186/s12890-017-0401-y · 2017
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
10.1056/nejmoa1001278 · 2010
Step-Up therapy in black children and adults with poorly controlled asthma
10.1056/nejmoa1905560 · 2019
Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
10.3310/hgwt3617 · 2025
A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma
10.1183/13993003.01100-2016 · 2017
Tiotropium is efficacious in 6- to 17-Year-Olds with asthma, independent of T2 phenotype
10.1016/j.jaip.2019.03.019 · 2019
Unresolved referenced work
2024
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
10.1542/peds.108.2.e36 · 2001
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
10.1016/j.jaci.2009.09.021 · 2009
Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: a placebo-controlled randomized trial
10.1371/journal.pone.0182411 · doi-reference
Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial
10.1016/s2213-2600(15)00500-7 · doi-reference
Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial
10.1001/jama.2015.13896 · doi-reference
Daily or intermittent budesonide in preschool children with recurrent wheezing
10.1056/nejmoa1104647 · doi-reference
Regular vs prn nebulized treatment in wheeze preschool children
10.1111/j.1398-9995.2009.02134.x · doi-reference
Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis
10.1542/peds.2015-4496 · doi-reference
Weighted breaths: exploring biologic and non-biologic therapies for Co-Existing asthma and obesity
10.1007/s11882-024-01153-x · doi-reference
A multifactorial weight reduction programme for children with overweight and asthma: a randomized controlled trial
10.1371/journal.pone.0157158 · doi-reference
Effects of obesity on response to asthma biologic treatment: longitudinal data from the United Kingdom severe asthma registry
10.1016/j.jaip.2025.07.041 · doi-reference
Obesity-related asthma: a pathobiology-based overview of existing and emerging treatment approaches
10.1164/rccm.202406-1166so · doi-reference
Obesity-Associated Non-T2 mechanisms in Obese asthmatic individuals
10.3390/biomedicines11102797 · doi-reference
Overweight, obesity, and lung function in children and Adults-A meta-analysis
10.1016/j.jaip.2017.07.010 · doi-reference
Decreased response to inhaled steroids in overweight and obese asthmatic children
10.1016/j.jaci.2010.12.010 · doi-reference
Obesity and asthma: an association modified by age of asthma onset
10.1016/j.jaci.2011.03.036 · doi-reference
Management strategies to reduce exacerbations in non-T2 asthma
10.1016/j.jaip.2021.04.033 · doi-reference
Azithromycin for poorly controlled asthma in children: a randomized controlled trial
10.1016/j.chest.2022.02.025 · doi-reference
Mometasone or tiotropium in mild asthma with a low sputum eosinophil level
10.1056/nejmoa1814917 · doi-reference
Tezepelumab in adults and adolescents with severe, uncontrolled asthma
10.1056/nejmoa2034975 · doi-reference
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
10.1186/s12931-020-01526-6 · doi-reference
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
10.1016/j.jaci.2023.09.044 · doi-reference
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma
10.1111/all.15743 · doi-reference
Dupilumab in children with uncontrolled moderate-to-severe asthma
10.1056/nejmoa2106567 · doi-reference
Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma
10.1056/nejmoa1804092 · doi-reference
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
10.1016/s2213-2600(17)30344-2 · doi-reference
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
10.1183/13993003.00936-2018 · doi-reference
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
10.1016/s0140-6736(16)31324-1 · doi-reference
Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
10.1016/s0140-6736(16)31322-8 · doi-reference
Activated sputum eosinophils associated with exacerbations in children on mepolizumab
10.1016/j.jaci.2024.01.031 · doi-reference
Controversies in allergy: are biologic treatment responses in severe asthma the same in adults and children?
10.1016/j.jaip.2023.07.028 · doi-reference
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial
10.1016/s0140-6736(22)01198-9 · doi-reference
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
10.1186/s13223-019-0366-x · doi-reference
Aeroallergen sensitization, serum IgE, and eosinophilia as predictors of response to omalizumab therapy during the fall season among children with persistent asthma
10.1016/j.jaip.2020.03.051 · doi-reference
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations
10.1016/j.jaci.2015.09.008 · doi-reference
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children
10.1056/nejmoa1009705 · doi-reference
Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents
10.1016/j.jaip.2013.01.011 · doi-reference
Treatment benefit with omalizumab in children by indicators of asthma severity
10.1016/j.jaip.2020.03.033 · doi-reference
“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
10.1016/j.rmed.2009.06.014 · doi-reference
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study
10.1164/rccm.201208-1414oc · doi-reference